Amphastar Pharma (AMPH) Tops Q3 EPS by 5c

Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.07, $0.05 better than the analyst estimate of $0.02. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $57.2 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
• Lumentum shares rise on analyst upgrades, AI demand outlook